SEC Form 4 · accession 0001387131-16-004575
TherapeuticsMD, Inc. · TXMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Cooper C. Collins
Director
Period of report
Mar 10, 2016
Accepted (ET)
Mar 14, 2016 · 5:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000025743
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 11, 2016 | P | 16,000 | $6.2323 | A | 36,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These shares were purchased in multiple transactions at prices ranging from $6.18 to $6.29, inclusive; the price reported reflects the weighted average price. The reporting person undertakes to provide to TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.